News headlines about Amphastar Pharmaceuticals (NASDAQ:AMPH) have been trending somewhat positive on Friday, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the company an impact score of 43.634329645378 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
A number of equities analysts recently weighed in on AMPH shares. Piper Jaffray Companies reiterated a “buy” rating and issued a $19.00 price target on shares of Amphastar Pharmaceuticals in a research report on Sunday, September 17th. BidaskClub lowered Amphastar Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday. Needham & Company LLC increased their price target on Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Friday, December 1st. Zacks Investment Research lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Finally, Jefferies Group set a $19.00 price target on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, October 29th. Two analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $19.50.
Amphastar Pharmaceuticals (AMPH) opened at $18.16 on Friday. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.08 and a quick ratio of 1.86. Amphastar Pharmaceuticals has a 1 year low of $12.05 and a 1 year high of $19.95. The firm has a market capitalization of $819.29, a price-to-earnings ratio of 120.40, a P/E/G ratio of 1.27 and a beta of 1.69.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a return on equity of 2.30% and a net margin of 0.12%. The business had revenue of $57.90 million during the quarter, compared to analyst estimates of $57.23 million. During the same quarter last year, the company posted $0.14 EPS. Amphastar Pharmaceuticals’s revenue for the quarter was down 9.8% on a year-over-year basis. research analysts expect that Amphastar Pharmaceuticals will post -0.03 earnings per share for the current fiscal year.
In other Amphastar Pharmaceuticals news, Director Stephen B. Shohet sold 7,862 shares of the firm’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $19.25, for a total transaction of $151,343.50. Following the completion of the sale, the director now directly owns 31,978 shares in the company, valued at approximately $615,576.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO William J. Peters sold 6,226 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $19.67, for a total value of $122,465.42. The disclosure for this sale can be found here. Insiders have sold a total of 81,172 shares of company stock valued at $1,513,538 over the last 90 days. Corporate insiders own 11.10% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/12/amphastar-pharmaceuticals-amph-earns-daily-coverage-optimism-score-of-0-20.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.